Results 81 to 90 of about 91,175 (237)

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome accounting for half of heart failure cases. Although natriuretic peptides are the most accepted and extensively used biomarkers for heart failure, their diagnostic accuracy for HFpEF remains debatable.
Reza Parvan, Natale Rolim, Andreas B. Gevaert, Alessandro Cataliotti, Emeline M. van Craenenbroeck, Volker Adams, Ulrik Wisløff, Gustavo Jose Justo Silva, on behalf of the OptimEx Study Group   +8 more
wiley   +1 more source

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high‐, middle‐ and low‐income countries – A Global Congestive Heart Failure (G‐CHF) study

European Journal of Heart Failure, EarlyView.
Abstract Aims The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels. Methods and results We enrolled 17 321 participants with HF from 40 countries.
Darryl P. Leong, Philip G. Joseph, Hisham Dokainish, Stefan Störk, John V.V. McMurray, Lisa M. Mielniczuk, Sanjib Kumar Sharma, Andrés Orlandini, Kamilu M. Karaye, Antoni Bayes‐Genis, Tara McCready, Alex Grinvalds, Kumar Balasubramanian, Kelley R. Branch, Kristian Kragholm, Salim Yusuf, on behalf of the G‐CHF Investigators   +16 more
wiley   +1 more source

Electrocardiographic parameter profiles for differentiating hypertrophic cardiomyopathy stages. [PDF]

J Arrhythm
Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Faheem MSB, Khatri N, Cheema S, Zahid MR, Samadi S.   +4 more
europepmc   +2 more sources

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler   +15 more
wiley   +1 more source

The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)

European Journal of Heart Failure, EarlyView.
Abstract This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.
Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes‐Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats   +20 more
wiley   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

European Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa   +19 more
wiley   +1 more source

Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome

European Journal of Heart Failure, EarlyView.
Lipidome changes in anthracycline‐induced cardiotoxicity (AIC). Aims Anthracyclines are key components of various chemotherapy regimens, but their clinical utility is limited by severe cardiotoxic side effects. Previous studies have suggested that anthracycline‐induced cardiotoxicity (AIC) may be driven by alterations in myocardial lipid metabolism ...
Vera M. Braun, Anna Foryst‐Ludwig, Ulf Landmesser, István Baczkó, Hendrik Milting, Ulrich Kintscher, Niklas Beyhoff   +6 more
wiley   +1 more source

Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]

, 2020
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark, Paik, David T, Wu, Joseph C   +2 more
core  

Prediction and prognostic role of left ventricular systolic dysfunction in family screening for dilated cardiomyopathy and non‐dilated left ventricular cardiomyopathy

European Journal of Heart Failure, EarlyView.
Aims The prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear.
Eva Del Mestre, Alessia Paldino, Carola Pio Loco Detto Gava, Ilaria Gandin, Marta Gigli, Davide Stolfo, Martina Setti, Giovanni Maria Severini, Beatrice Spedicati, Stefania Lenarduzzi, Giorgia Girotto, Alessandro Folgheraiter, Jacopo Giulio Rizzi, Renata Korcova, Luisa Mestroni, Marco Merlo, Matteo Dal Ferro, Gianfranco Sinagra   +17 more
wiley   +1 more source